Gut Microbes May Predict Survival in Dogs Receiving Cancer Immunotherapy

For decades, oncologists have chased a deceptively simple question: why do some patients respond brilliantly to cancer immunotherapy while others gain little or no benefit? In human medicine, one increasingly persuasive answer lies not in the tumor itself but in the trillions of microbes inhabiting the gut. Now, that idea has crossed the species barrier. In a pilot study published in the journal Veterinary Oncology, researchers report that the gut microbiota of dogs with cancer—sampled before the animals received an experimental anti-EGFR/HER2 vaccine—harbored bacterial signatures strongly associated with how long the animals lived. The findings mark the first time that gut microbial taxa have been linked to survival in dogs undergoing cancer immunotherapy, and they open a provocative new front in veterinary and comparative oncology.

The study emerged from a confluence of two research currents. Cancer remains the leading cause of death in dogs, yet veterinary oncology has lagged behind its human counterpart, particularly in immunotherapy. Immune checkpoint inhibitors, which revolutionized human cancer care, have only just begun entering canine clinical trials. In parallel, however, other immunotherapeutic approaches have advanced in dogs over the past decade. Among them is a vaccine designed to stimulate immunity against EGFR and HER2, two cell-surface proteins frequently exploited by tumors. Earlier work showed that this vaccine could provoke anti-tumor activity in both T cells and B cells and reduce metastatic burden in canine patients. Meanwhile, in human oncology, a growing body of evidence has tied gut microbiome composition to immunotherapy outcomes, spurring clinical trials of fecal microbiota transplants as adjuncts to checkpoint blockade. What remained entirely unexplored was whether the same microbiome-survival relationship exists in dogs receiving anti-cancer immunization.

To find out, a collaboration spanning the National Cancer Institute, Oregon State University, Yale University, and the Bridge Animal Referral Center in Edmonds, Washington, enrolled 51 canine cancer patients in a clinical trial of the EGFR/HER2 peptide vaccine. The cohort included 28 females and 34 purebred dogs, with a mean age at diagnosis of 9.5 years. The most common diagnosis was osteosarcoma, a malignant bone tumor affecting 22 dogs, followed by hemangiosarcoma, an aggressive cancer of blood-forming vessels, in 8 dogs; the remaining 21 animals carried a mix of other tumor types. On the day each dog received its first vaccine dose, the team collected rectal swabs to capture the baseline gut microbiome—the microbial community as it existed before any vaccine-driven immune changes could take hold. All animals also continued to receive standard veterinary care, and the patients were scheduled to receive two vaccine injections three weeks apart.

The laboratory work relied on 16S rRNA gene sequencing, a standard technique that reads a conserved bacterial gene to identify which microbes are present and in what proportions. DNA extracted from the swabs was amplified and barcoded at the National Cancer Institute’s Microbiome and Genetics Core Facility and sequenced on an Illumina MiSeq platform, yielding an average of roughly 32,000 reads per sample and a total of 899 amplicon sequence variants—the fine-grained units used to distinguish bacterial populations. Bioinformatic pipelines built on DADA2 and QIIME2 processed the reads, assigned taxonomy against the SILVA reference database, and predicted functional potential using PICRUSt2. The team then applied survival analysis, including Kaplan-Meier curves and Cox proportional hazards regression, to ask a single pointed question: did the abundance of any bacterial taxon at baseline correlate with how long each dog lived?

The first results were, in a sense, reassuringly unremarkable. Neither alpha diversity—the richness and evenness of microbes within a sample—nor beta diversity, which measures compositional differences between samples, varied significantly by cancer type, sex, or breed. No specific taxa or predicted functional pathways distinguished one diagnostic group from another. Within the limits of the sample size, the canine gut microbiome did not appear to encode a signature of tumor type. But that null result carried an important implication: it suggested the study population carried no inherent microbiome bias that could confound the search for survival-related microbes. The microbiome differences the team eventually found would therefore be less likely to reflect pre-existing differences between cancer groups.

Clinical covariates told a familiar story. Dogs with hemangiosarcoma and dogs older than 11.9 years at diagnosis had significantly poorer survival, consistent with prior veterinary reports, while breed made no difference. Neither recent antibiotic use, chemotherapy, nor surgery predicted outcome. Armed with these confounders, the researchers ran Cox regression separately within the osteosarcoma and other-cancer subgroups, deliberately excluding hemangiosarcoma because its grim prognosis and small sample size could distort the analysis. Under a relaxed false discovery rate threshold, they identified 57 survival-associated taxa among osteosarcoma patients and 46 among the other-cancer group. Crucially, 15 taxa appeared in both groups, and 11 of those—73 percent—pointed in the same direction in each, with matching hazard ratios. That convergence across biologically distinct tumors hinted at shared microbial signatures tied to survival rather than to any single malignancy.

When the team pooled all 51 dogs, including the hemangiosarcoma cases, the signal strengthened rather than dissolving. All 11 taxa remained significantly associated with survival under the stricter criterion of a false discovery rate below 0.1. Seven taxa, when abundant, were linked to an elevated risk of death, while four were associated with prolonged survival. Kaplan-Meier curves built on uniform low-versus-high abundance thresholds made the separation visible across the entire cohort. The associations also withstood the study’s most stringent test: after statistically adjusting for hemangiosarcoma diagnosis and advanced age—the two strongest predictors of poor outcome—every one of the 11 microbes retained its significant relationship with survival, confirming the robustness of the microbial signal in the face of powerful clinical confounders.

Which microbes made the list? While the full taxonomic details reside in the study’s supplementary tables, the published discussion highlights several recognizable genera. Some, such as Enterococcus and Ruminiclostridium, showed associations that diverge from certain human studies, a discrepancy the authors attribute partly to differences in treatment modality and partly to the resolution limits of 16S sequencing, which often cannot identify bacteria at the species or strain level—precisely the classifications most likely to share functional traits. Others, including Flavonifractor, members of the Lachnospiraceae family, and Shigella, have been reported in human cancer immunotherapy research with directions of effect that echo the canine findings. The partial overlap, and partial divergence, underscores both the promise and the early stage of cross-species microbiome oncology: canine and human gut communities are related but not identical, and therapies differ fundamentally between the species.

The authors are careful about what the study can and cannot claim. A baseline sample taken before vaccination cannot, by itself, prove whether the 11 taxa are general prognostic markers of cancer survival or biomarkers specific to the anti-EGFR/HER2 immunotherapy response—though their independence from cancer type, age, and poor-prognosis factors tips the balance toward the latter interpretation. The cohort of 51 dogs was too small to resolve cancer-type-specific biomarkers, and diet data, a major microbiome determinant, were unavailable. Generalizing the results will require larger cohorts and independent validation, which the collaborative group says it is actively pursuing. Still, the mechanistic stakes are high. Gut microbes have been shown in mouse models and human patients to either enhance or blunt immunotherapy effects, and the systemic immune influence of the gut may reach even anatomically distant tumors like osteosarcomas of the bone.

The road ahead, the researchers argue, runs from correlation toward causation. Computational approaches designed to infer causal relationships from observational data—Mendelian randomization, transkingdom network analysis, and mediation analysis—could help identify microbes that do not merely flag better survival but actively drive it. The ultimate test would be interventional: randomized clinical trials of fecal microbiota transplants or anti-cancer probiotics in dogs undergoing immunotherapy. If those experiments succeed, the implications could flow in both directions across the species line. Dogs develop spontaneously occurring cancers in a way few laboratory models replicate, making veterinary oncology a genuine translational bridge. Eleven bacterial taxa, measured from a simple rectal swab on the day of a first vaccine dose, may prove to be the first microbiome-based prognostic tools in canine cancer—and a comparative oncology resource that could ultimately sharpen immunotherapy for human patients as well.

Subject of Research: Gut microbiome biomarkers of survival in dogs with cancer receiving anti-EGFR/HER2 immunotherapy

Article Title: Gut microbiota of dogs with cancer receiving anti-EGFR/HER2 immunization reveals potential biomarkers of patient survival

Article References: Rodrigues, R. R., Karumuru, V., Nuss, S., Elliott, M., Shriver, I., Chao, C.-M., Berriatua, R. C., Doyle, H. A., Tripp, C., Mamula, M. J., Dzutsev, A., Morgun, A., & Shulzhenko, N. (2025). Gut microbiota of dogs with cancer receiving anti-EGFR/HER2 immunization reveals potential biomarkers of patient survival. Veterinary Oncology, 2(1), Article 36. https://doi.org/10.1186/s44356-025-00048-x

Image Credits: AI Generated

DOI: 10.1186/s44356-025-00048-x

Keywords: canine cancer, gut microbiome, immunotherapy, EGFR/HER2 vaccine, 16S rRNA sequencing, survival biomarkers, veterinary oncology, Cox regression, osteosarcoma, hemangiosarcoma, comparative oncology, fecal microbiota transplant